PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Abstract

BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and also some undertreatment, which may be reduced by tailoring adjuvant treatment to the patients' risk of recurrence based on molecular tumor characteristics. PRIMARY OBJECTIVES: To compare the rates of vaginal recurrence in women with high-intermediate risk endometrial cancer, treated after surgery with molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy or with standard adjuvant vaginal brachytherapy STUDY HYPOTHESIS: Adjuvant treatment based on a molecular-integrated risk profile provides similar local control and recurrence-free survival as current standard adjuvant brachytherapy in patients with high-intermediate risk endometrial cancer, while sparing many patients the morbidity of adjuvant treatment and reducing healthcare costs. TRIAL DESIGN: A multicenter, international phase III randomized trial (2:1) of molecular-integrated risk profile-based adjuvant treatment (experimental arm) or adjuvant vaginal brachytherapy (standard arm). MAJOR INCLUSION/EXCLUSION CRITERIA: Women aged 18 years and over with a histological diagnosis of high-intermediate risk endometrioid endometrial cancer after total abdominal or laparoscopic hysterectomy and bilateral salpingo-oophorectomy. High-intermediate risk factors are defined as: (i) International Federation of Gynecology and Obstetrics stage IA (with invasion) and grade 3; (ii) stage IB grade 1 or 2 with age ≥60 and/or lymph-vascular space invasion; (iii) stage IB, grade 3 without lymph-vascular space invasion; or (iv) stage II (microscopic and grade 1). ENDPOINTS: The primary endpoint is vaginal recurrence. Secondary endpoints are recurrence-free and overall survival; pelvic and distant recurrence; 5-year vaginal control (including treatment for relapse); adverse events and patient-reported symptoms and quality of life; and endometrial cancer-related healthcare costs. SAMPLE SIZE: 500 eligible and evaluable patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Estimated date for completing accrual will be late 2021. Estimated date for presentation of (first) results is expected in 2023. TRIAL REGISTRATION: The trial is registered at clinicaltrials.gov (NCT03469674) and ISRCTN (11659025).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 14

1. 1.

   Colombo N, Creutzberg C, Amant F, et al ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016;26:2–30.

   Not in our library10.1097/igc.0000000000000609

2. 2.

   ASTEC/EN.5 Study Group, Blake P, Swart AM, et al Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137–46.

   Not in our library10.1016/s0140-6736(08)61767-5

3. 3.

   Creutzberg CL, van Putten WLJ, Koper PCM, et al Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000;355:1404–11.

   Not in our library10.1016/s0140-6736(00)02139-5

4. 4.

   Keys HM, Roberts JA, Brunetto VL, et al A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–51.

   Not in our library10.1016/j.ygyno.2003.11.048

5. 5.

   Nout RA, Smit VTHBM, Putter H, et al Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816–23.

   Not in our library10.1016/s0140-6736(09)62163-2

6. 6.

   Creutzberg CL, Nout RA, Lybeert MLM, et al Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631–8.

   Not in our library10.1016/j.ijrobp.2011.04.013

7. 7.

   Bosse T, Peters EEM, Creutzberg CL, et al Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015;51:1742–50.

   Not in our library10.1016/j.ejca.2015.05.015

8. 8.
   Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy · 2018

   No notice
9. 9.

   Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.

   Not in our library10.1038/nature12113

10. 10.

    Talhouk A, McConechy MK, Leung S, et al A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.

    Not in our library10.1038/bjc.2015.190

11. 11.

    Stelloo E, Nout RA, Osse EM, et al Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22:4215–24.

    Not in our library10.1158/1078-0432.ccr-15-2878

12. 12.
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile · 2018

    No notice
13. 13.

    Wortman BG, Bosse T, Nout RA, et al Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol 2018;151:69–75.

    Not in our library10.1016/j.ygyno.2018.07.020

14. 14.
    Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas · 2020

    No notice

Cited by papers we hold 4

• Novel molecular classification of endometrial cancer - current and future clinical implications · 2023
  Not checked
• Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma · 2022
  Not checked
• New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines · 2021
  No notice
• Cancer of the corpus uteri: 2021 update · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.